KG
Therapeutic Areas
Evofem Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Phexxi® (lactic acid, citric acid and potassium bitartrate) | On-demand prescription contraception | Approved |
| Solosec® (secnidazole) | Bacterial vaginosis and trichomoniasis | Approved |
| EVO200 | Prevention of recurrent Bacterial Vaginosis (BV) | Phase 1 |
| MPT Product Candidate (with OB-002) | Prevention of human immunodeficiency virus (HIV) | Preclinical |
Leadership Team at Evofem Biosciences
SP
Saundra Pelletier
Chief Executive Officer, President, Executive Director and interim Chair of the Board
IZ
Ivy Zhang
Chief Financial Officer and Secretary
AR
Amy Raskopf
Chief Business Development Officer
ET
Ellen Thomas
Chief of Staff
KK
Kim Kamdar, Ph.D.
Member of the Board of Directors; Chair, Governance and Nominating Committee
TO
Tony O'Brien
Member of the Board of Directors